MTSR - NASDAQ
Metsera, Inc.
$70.50
+0.0000%Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
At a Glance
Live SnapshotMetsera, Inc. Management Team
Mr. Michael Donovan
Chief Design Officer
Ms. Nancye Green
Chief Experience Officer
Ms. Melissa Enbar
Chief Human Resources Officer
Mr. Matthew Lang J.D.
Chief Legal Officer & Secretary
Dr. Steven Marso M.D.
Chief Medical Officer
Dr. Brian Hubbard Ph.D.
Chief Scientific Officer
Compensation
$582,969
Mr. Daniel Hoey
Chief Technical Operations Officer
Dr. Clive A. Meanwell M.D., Ph.D.
Co-Founder & Executive Chairman
Compensation
$142,913
Mr. Paul L. Berns
Co-Founder & Lead Independent Director
Mr. Christopher J. Visioli
Co-Founder, Chief Financial Officer & Chief Business Officer
Compensation
$292,308
Mr. Christopher Whitten Bernard
Co-Founder, President, Chief Executive Officer & Director
Compensation
$763,182
Dr. Gbolahan Amusa Benz C.F.A., M.D.
EVice President of Strategic Finance & Investor Relations
Compensation
$496,798
Metsera, Inc. Insider Positioning
During the last 12 months, insiders have sold $21K worth of MTSR shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
193
11.82K
-12K
-$12K
9-12 Months
0
0.00
268
9.65K
-10K
-$10K
Top Buyers
No buying activity
Top Sellers
Fmr Llc
10 Percent Owner, Other: See Remark 1
$21K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $21K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
1 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
MTSR - Filing history and reports
No SEC filings available for MTSR
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.